Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
9799518
Reference Type
Journal Article
Subtype
Review
Title
Chronic urticaria and autoimmune thyroid disease: is there a link?
Author(s)
Rottem, M
Year
2003
Is Peer Reviewed?
Yes
Journal
Autoimmunity Reviews
ISSN:
1568-9972
EISSN:
1873-0183
Volume
2
Issue
2
Page Numbers
69-72
Language
English
PMID
12848961
DOI
10.1016/s1568-9972(02)00141-6
Abstract
Chronic idiopathic urticaria (CIU) is a common and frustrating disorder. A subset of patients with CIU has been classified as autoimmune on the basis of two main findings: association with thyroid autoimmunity and anti-IgE and/or anti-IgE receptor antibodies. There is growing evidence that some cases of CIU are associated with thyroid autoimmunity. Patients with CIU have an increased frequency of Hashimoto thyroiditis with the presence of antibodies to thyroglobulin or a microsomal-derived antigen (peroxidase), even in euthyroid patients. No broad non-specific autoimmunity is present. Antibodies reactive with Fc(epsilon)RI, the high-affinity IgE receptor are found in sera of 10-40% of patients with CIU. A smaller subset of patients with CIU lack anti-Fc(epsilon)RI antibodies and have anti-IgE antibodies that cross-link Fc(epsilon)RIs occupied by IgE. There are a minority of CIU patients that lack such antibodies, but can degranulate basophils by a serum factor that has not yet been determined. Most patients with anti-IgE antibodies have an IgG antibody directed against the 34 kd alpha subunit of the IgE receptor. There are no data to suggest that any of the anti thyroid antibodies is pathogenic in terms of CIU, and most likely these are associated, parallel, autoimmune events. Screening for thyroid autoimmunity and function is advisable in all patients with CIU for the early identification of patients requiring either treatment of underlying thyroid dysfunction or follow-up.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity